Clinical Outcomes after Treatment of Periodontal Intrabony Defects with Nanocrystalline Hydroxyapatite (Ostim) or Enamel Matrix Derivatives (Emdogain): A Randomized Controlled Clinical Trial
Table 2
Clinical outcomes at 6 and 12 months.
Variable
Baseline (BS)
6 months
12 months
Difference (after 6 m)
P value* (Bs–6 m)
Difference (after 12 m)
P value* (Bs–12 m)
P value* (6 m–12 m)
Bone level (mm, mean ± SD)
NHA group
0.001
<0.001
0.886
EMD group
<0.001
<0.001
0.919
P value†
0.867
0.836
0.867
0.958
1.000
RAL (mm, mean ± SD)
NHA group
0.004
0.003
0.802
EMD group
<0.001
<0.001
0.635
P value†
0.640
0.783
0.528
0.427
0.211
PPD (mm, mean ± SD)
NHA group
<0.001
<0.001
0.706
EMD group
<0.001
<0.001
0.936
P value†
0.879
0.191
0.154
0.425
0.312
RGR (mm, mean ± SD)
NHA group
0.001
0.001
0.891
EMD group
<0.001
0.001
0.552
P value†
0.352
0.518
0.596
0.946
0.785
EMD: enamel matrix derivative; NHA: nanocrystalline hydroxyapatite; PPD: probing pocket depths; RAL: relative attachment level; RGR: relative gingival recession; *paired t-test; †unpaired t-test. Mean differences are calculated as baseline 6–months, baseline–12 months, and 6–12 months.